Related Experiment Video
Updated: Jun 22, 2025

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
Published on: January 24, 2025
Nanosimilars: A Scientific or A Regulatory Debate?
Costas Demetzos1,2,3
1School of Health Sciences, Department of Pharmacy, Section of Pharmaceutical Technology, Laboratory of Pharmaceutical Nanotechnology, National & Kapodistrian University of Athens, Athens, Greece. demetzos@pharm.uoa.gr.
Abstract:
The paper highlights the necessity for a robust regulatory framework for assessing nanomedicines and their off-patent counterparts, termed as nanosimilar, which could be considered as 'similar' to the prototype nanomedicine,based on essential criteria describing the 'similarity'. The term 'similarity' should be focused on criteria that describe nanocarriers, encompassing their physicochemical, thermodynamic, morphological, and biological properties, including surface interactions and pharmacokinetics. Nanocarriers can be regarded as advanced self-assembled excipients (ASAEs) due to their complexity and chaotic behavior and should be evaluated by using essential criteria in order for off-patent nanomedicines be termed as nanosimilars, from a regulatory perspective. Collaboration between the pharmaceutical industry, regulatory bodies, and artificial intelligence (AI) startups is pivotal for the precise characterization and approval processes for nanomedicines and nanosimilars and embracing innovative tools and terminology facilitates the development of a sustainable regulatory framework, ensuring safety and efficacy. This crucial shift toward precision R&D practices addresses the complexity inherent in nanocarriers, paving the way for therapeutic advancements with economic benefits.
More Related Videos
04:55Testing of Nanoparticle Release from a Composite Containing Nanomaterial Using a Chamber System
Published on: November 22, 2016
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Related Concept Videos
Drug Regulation
Factors Affecting Dissolution: Particle Size and Effective Surface Area
Bioequivalence: Overview
Drug Nomenclature
Drug Control Governance: Regulatory Bodies and Their Impact